Skip to main content
. 2020 Mar 18;9(10):3390–3399. doi: 10.1002/cam4.2998

Figure 1.

Figure 1

A, Event Free Survival of CLL patients who started therapy with standard dose ibrutinib (420 mg daily) compared to reduced dose ibrutinib (<420 mg daily) B, Overall Survival of CLL patients who started therapy with standard dose ibrutinib (420 mg daily) compared to reduced dose ibrutinib (<420 mg daily)